scholarly journals A cost-utility analysis of risk model-guided versus physician’s choice antiemetic prophylaxis in patients receiving chemotherapy for early-stage breast cancer: a net benefit regression approach

2017 ◽  
Vol 25 (8) ◽  
pp. 2505-2513 ◽  
Author(s):  
Kednapa Thavorn ◽  
Doug Coyle ◽  
Jeffrey S. Hoch ◽  
Lisa Vandermeer ◽  
Sasha Mazzarello ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Model ◽  
Early Stage ◽  
Cost Utility ◽  
Cost Utility Analysis ◽  
Early Stage Breast Cancer ◽  
Utility Analysis ◽  
Net Benefit ◽  
Antiemetic Prophylaxis ◽  
Regression Approach

scholarly journals OC-103: IORT Treatment in The Early Stage Breast Cancer patients – A Cost Utility Analysis

2019 ◽  
Vol 141 ◽  
pp. S43
Author(s):  
T. Tungkasamit ◽  
I. Chaiwiriyabunya ◽  
N. Munpolsri ◽  
K. Kengkla ◽  
S. Saokaew
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Early Stage ◽  
Cost Utility ◽  
Cost Utility Analysis ◽  
Early Stage Breast Cancer ◽  
Breast Cancer Patients ◽  
Utility Analysis

scholarly journals Risk Model–Guided Antiemetic Prophylaxis vs Physician’s Choice in Patients Receiving Chemotherapy for Early-Stage Breast Cancer

JAMA Oncology ◽  
2016 ◽  
Vol 2 (2) ◽  
pp. 225 ◽  
Author(s):  
Mark Clemons ◽  
Nathaniel Bouganim ◽  
Stephanie Smith ◽  
Sasha Mazzarello ◽  
Lisa Vandermeer ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Model ◽  
Early Stage ◽  
Early Stage Breast Cancer ◽  
Antiemetic Prophylaxis

Cost–Utility Analysis of Palonosetron-Based Therapy in Preventing Emesis Among Breast Cancer Patients

2010 ◽  
Vol 8 (6) ◽  
pp. 242-251 ◽  
Author(s):  
Elenir B.C. Avritscher ◽  
Ya-Chen T. Shih ◽  
Charlotte C. Sun ◽  
Richard J. Gralla ◽  
Steven M. Grunberg ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Cost Utility ◽  
Cost Utility Analysis ◽  
Breast Cancer Patients ◽  
Utility Analysis
Sign in / Sign up

Export Citation Format

Share Document